# Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients

> **NCT00585221** · PHASE2 · TERMINATED · sponsor: **University of Utah** · enrollment: 8 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors
- Cancer Brain
- Solid Tumors

## Interventions

- **DRUG:** Peginterferon-alpha 2b (PegIFNa2b);
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT00585221
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** PI terminated at the recommendation of DSMC \& IRB
- **Last updated:** 2017-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00585221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00585221, "Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00585221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*